Related Experiment Video

Updated: Aug 30, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

Cardiovascular disease in type 2 diabetics: epidemiology, risk factors and therapeutic modalities

Mogher Khamaisi1, Isaiah D Wexler, Jan Skrha

  • 1Diabetes Center, Department of Internal Medicine, Hadassah University Hospital, Jerusalem, Israel. murir@hadassah.org.il

The Israel Medical Association Journal : IMAJ
|December 3, 2003
PubMed

Insights

Type 2 diabetes and chronic hyperglycemia significantly increase cardiovascular disease risk. Managing traditional risk factors and achieving optimal glycemic control are crucial for preventing macrovascular complications.

Area of Science:

  • Cardiology
  • Endocrinology
  • Diabetology

Background:

  • Type 2 diabetes mellitus (T2DM) is a growing global health concern, with macrovascular complications being a primary cause of mortality.
  • Accelerated atherosclerosis, leading to cardiovascular and cerebrovascular events, is prevalent in T2DM patients.
  • Numerous risk factors, including hyperlipidemia, hypertension, obesity, and smoking, are amplified in diabetic individuals.

Purpose of the Study:

  • To highlight the significant association between chronic hyperglycemia in T2DM and macrovascular complications.
  • To underscore the role of both traditional and diabetes-specific factors in the development of cardiovascular disease (CVD).
  • To emphasize the independent risk posed by hyperglycemia to CVD development.

Main Methods:

  • Review of existing literature on risk factors for CVD in T2DM patients.
  • Analysis of the impact of hyperglycemia on atherosclerosis and vascular damage.
  • Examination of the relationship between glycemic control and CVD risk.

Main Results:

  • Hyperglycemia is an independent and significant risk factor for CVD in T2DM.
  • Elevated post-prandial and fasting blood glucose levels correlate directly with increased CVD risk.
  • Factors like hypercholesterolemia, hypertension, inflammation, and genetic susceptibility contribute to CVD in T2DM.

Conclusions:

  • Optimal glycemic and metabolic control are essential for reducing CVD development in T2DM.
  • Comprehensive management strategies must address both traditional and diabetes-specific risk factors.
  • Further research is needed to fully elucidate the clinical relevance of various contributing factors.

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...
Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...